


Lymphoma Epidemiology of Outcomes (LEO)



Spot Map of LEO Participants Location as of 2019

- Cornell University
- MD Anderson
- University of Rochester
- Emory
- University of Iowa
- Washington University
- Mayo Clinic
- University of Miami



A Spot Map is a tool researchers use to display information about study participants. This spot map uses dots to show where each study participant lived at the time they signed up for the study, along with the medical center where they agreed to participate.

Who we are

The LEO study is a joint effort between 8 prominent medical centers and universities around the United States. The goal is to build a large and diverse dataset of cancer patients similar to yourself. We hope to identify several factors that impact lymphoma survivorship.

What we do

We collect data and samples that will help us understand the causes for different types of lymphomas, how we can better treat them, and the best ways to help survivors. Your continued participation in this study is the key to our success!

How to learn more

Visit our website at
www.leocohort.org

Contact us at leocohort@mayo.edu

See page 2 for results from one of our recent publications and Q&A's

Featured LEO Publication

'The association of physical activity before and after lymphoma diagnosis with survival outcomes.'

Summary & Results

Using information gathered from study participants, we found that those who exercised at least 150 minutes per week of moderate activity were significantly more likely to have a better overall survival rate and lymphoma-specific survival rate at their 3-year follow-up. We reported similar results for participants who did vigorous activity for at least 75 minutes per week, according to American Cancer Society guidelines. This data suggests that increasing your physical activity plays an important role in overall lymphoma survivorship. We suggest asking your doctor how to safely meet these exercise guidelines.

Published in the American Journal of Hematology in
December of 2018, 93(12):1543-1550

LEO accrual by age as of **March 2020**

Age	Total	Percentage
18-30	297	4%
31-40	485	6%
41-50	895	12%
51-60	1761	23%
61-70	2191	29%
71-80	1521	20%
81+	439	6%
Total enrollment	7589	100%

Did you know our organization has published over 53 research papers since 2015?

We want to graciously thank you for your continued support and participation in our research. We can't do it without you!

For more information and links to all of our publications, visit our website www.leocohort.org

How will the LEO study benefit me?

The information you provide will help us gain a better understanding of Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, and Chronic Lymphocytic Leukemia. Your information will assist in improving patient care and quality of life to those with these diseases.

Will participating in LEO affect my cancer treatment?

No, it will not affect your medical treatment in any way.



What does participation mean?

- ✓ Provide informed consent
- ✓ Provide a blood sample at enrollment
- ✓ Complete questionnaires at enrollment and during follow-up